Information Provided By: 
Fly News Breaks for July 20, 2016
PTCT
Jul 20, 2016 | 10:08 EDT
Noting that NICE has finalized access for England for PTC Therapeutics' Translarna, Wedbush analyst Heather Behanna said she remains on the sidelines on PTC shares, citing the drug's continued regulatory and pricing risks in Europe. While keeping a Neutral rating and $12 price target on PTC shares, Behanna said she believes it is unlikely that the EMA will pull the drug from the market and sees "meaningful upside" in early 2017 if Translarna can demonstrate a statistically significant positive result in cystic fibrosis.
News For PTCT From the Last 2 Days
There are no results for your query PTCT
